Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT06083844
Title Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.